Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer - PubMed (original) (raw)

Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer

S S Jeetle et al. Virchows Arch. 2012 Aug.

Abstract

In vitro studies have implicated neuroendocrine differentiation in the development of hormone resistant prostate cancer following administration of androgen blockers. Studies on clinical material are equivocal. We wished to understand the significance of neuroendocrine differentiation in our large and well-characterised cohort of clinically localised prostate cancer, treated conservatively. Immunohistochemical expression of chromogranin-A was assessed semi-quantitatively on tissue samples of 806 patients in a tissue microarray approach. The correlation of expression with 10-year prostate cancer survival was examined. Multivariate analysis including contemporary Gleason score was performed and sub-group analysis of early hormone treated patients was also undertaken. Chromogranin-A expression correlated with high Gleason score (χ(2) = 28.35, p < 0.001) and early prostate cancer death (HR = 1.61, 95 %CI = 1.15-2.27, p < 0.001). In univariate analysis, NE differentiation correlated significantly with outcome (HR = 1.61, 95 % CI 1.15-2.27, p < 0.001) However in multivariate analysis including Gleason score, chromogranin-A expression was not an independent predictor of survival (HR = 0.97, 95 %CI = 0.89-1.37, p = 0.87). Although chromogranin-A expression was higher in patients with early hormone therapy (χ(2) = 7.25, p = 0.007), there was no association with prostate cancer survival in this sub-group (p = 0.083). Determination of neuroendocrine differentiation does not appear to have any bearing on the outcome of prostatic carcinoma and does not add to the established prognostic model.

PubMed Disclaimer

Similar articles

• Neuroendocrine differentiation in the progression of prostate cancer.
  Komiya A, Suzuki H, Imamoto T, Kamiya N, Nihei N, Naya Y, Ichikawa T, Fuse H. Komiya A, et al. Int J Urol. 2009 Jan;16(1):37-44. doi: 10.1111/j.1442-2042.2008.02175.x. Int J Urol. 2009. PMID: 19120524 Review.
• Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors.
  Genitsch V, Zlobec I, Seiler R, Thalmann GN, Fleischmann A. Genitsch V, et al. Int J Mol Sci. 2017 Jul 28;18(8):1640. doi: 10.3390/ijms18081640. Int J Mol Sci. 2017. PMID: 28788048 Free PMC article.
• The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.
  Berruti A, Bollito E, Cracco CM, Volante M, Ciccone G, Porpiglia F, Papotti M, Scarpa RM, Dogliotti L. Berruti A, et al. Prostate. 2010 May 15;70(7):718-26. doi: 10.1002/pros.21104. Prostate. 2010. PMID: 20087896
• Survival predictors in patients with prostate adenocarcinoma with hormonal blockade.
  Angulo JC, Redondo C, Sánchez-Chapado M, Colás B, Ropero S, López JI. Angulo JC, et al. Pathol Res Pract. 2016 Oct;212(10):899-903. doi: 10.1016/j.prp.2016.07.012. Epub 2016 Jul 27. Pathol Res Pract. 2016. PMID: 27502465
• Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
  Cussenot O, Villette JM, Cochand-Priollet B, Berthon P. Cussenot O, et al. Prostate Suppl. 1998;8:43-51. Prostate Suppl. 1998. PMID: 9690663 Review.

Cited by

• PET radiotracers for whole-body in vivo molecular imaging of prostatic neuroendocrine malignancies.
  Cohen D, Hazut Krauthammer S, Fahoum I, Kesler M, Even-Sapir E. Cohen D, et al. Eur Radiol. 2023 Sep;33(9):6502-6512. doi: 10.1007/s00330-023-09619-8. Epub 2023 Apr 13. Eur Radiol. 2023. PMID: 37052659 Review.
• Narrative review of challenges in the management of advanced neuroendocrine prostate cancer.
  Okasho K, Ogawa O, Akamatsu S. Okasho K, et al. Transl Androl Urol. 2021 Oct;10(10):3953-3962. doi: 10.21037/tau-20-1131. Transl Androl Urol. 2021. PMID: 34804838 Free PMC article. Review.
• Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
  Kaur H, Samarska I, Lu J, Faisal F, Maughan BL, Murali S, Asrani K, Alshalalfa M, Antonarakis ES, Epstein JI, Joshu CE, Schaeffer EM, Mosquera JM, Lotan TL. Kaur H, et al. Prostate. 2020 Sep;80(12):1012-1023. doi: 10.1002/pros.24035. Epub 2020 Jul 10. Prostate. 2020. PMID: 32649013 Free PMC article.
• Chromogranin A is a predictor of prognosis in patients with prostate cancer: a systematic review and meta-analysis.
  Guo Z, Wang Y, Xiang S, Wang S, Chan FL. Guo Z, et al. Cancer Manag Res. 2019 Apr 5;11:2747-2758. doi: 10.2147/CMAR.S190678. eCollection 2019. Cancer Manag Res. 2019. PMID: 31114331 Free PMC article.
• Androgen receptor signaling regulates T-type Ca2+ channel expression and neuroendocrine differentiation in prostate cancer cells.
  Hall M, Todd B, Allen ED Jr, Nguyen N, Kwon YJ, Nguyen V, Hearne JL, Martin-Caraballo M. Hall M, et al. Am J Cancer Res. 2018 Apr 1;8(4):732-747. eCollection 2018. Am J Cancer Res. 2018. PMID: 29736318 Free PMC article.

References

1. 1. Prostate Suppl. 1998;8:32-6 - PubMed
2. 1. Prostate. 2001 Jun 15;48(1):7-15 - PubMed
3. 1. J Urol. 2004 Apr;171(4):1513-9 - PubMed
4. 1. Int Urol Nephrol. 1999;31(1):75-82 - PubMed
5. 1. J Biol Chem. 2007 Feb 9;282(6):3571-83 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program